Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors

Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors

Solid Tumors

Ongoing, but not recruiting

1

Start Date 10/01/2007

Age of Trial (yrs) 17.2

Gleevec-resistant

HSP90 inhibitor

Destroy KIT

GIST not specified. GIST patient enrollment unknown.

9090-01

Synta Pharmaceuticals

See site contact info below

IV Intravenous

STA-9090 is a novel Hsp90 inhibitor. Based on pre-clinical data, it appears to be 10 to 100 times more potent than the geldanamycin family of Hsp90 inhibitors (such as 17AAG). Because of the increased potency, it appears to be able to inhibit a broader range of Hsp90 client proteins.
This phase I trial will give STA-9090 twice a week for 3 weeks followed by a one week drug holiday. A future phase I trial giving STA-9090 once a week for 3 weeks with a one week drug holiday is planned.